Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Concord Medical Reports Financial Results for the First Half of 2024


      News provided by

      Concord Medical Services Holdings Limited

      Sep 27, 2024, 07:00 ET

      Share this article

      Share this article


      BEIJING, Sept. 27, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2024[1].

      2024 First Half Highlights

      • Total net revenues were RMB218.8 million (US$30.1 million) in the first half of 2024, representing a 23.1% decrease from total net revenues of RMB284.5 million in the same period last year. Total net revenues included the net revenues from the hospital business of RMB137.8 million (US$19.0 million) and the net revenues from the network business of RMB81.0 million (US$11.1 million).
      • Gross loss was RMB41.6 million (US$5.7 million) in the first half of 2024, compared to the gross loss of RMB37.4 million in the first half of 2023. The gross loss margin was 19.0% for the first half of 2024, compared to 13.2% for the same period last year.
      • Net loss attributable to ordinary shareholders in the first half of 2024 was RMB172.3 million (US$23.7 million), compared to RMB91.0 million in the same period last year.
      • Basic and diluted loss per share for Class A and Class B ordinary shares in the first half of 2024 were both RMB1.31 (US$0.18), compared to RMB0.69 in the same period last year.
      • Non-GAAP[2] net loss in the first half of 2024 was RMB328.7 million (US$45.2 million), compared to non-GAAP net loss of RMB210.3 million in the same period last year. Non-GAAP basic and diluted loss per share for Class A and Class B ordinary shares in the first half of 2024 were both RMB1.31 (US$0.18), compared to RMB0.69 in the same period last year.
      • Adjusted EBITDA[3] (non-GAAP) was negative RMB148.0 million (US$20.4 million) in the first half of 2024, compared to negative RMB148.4 million in the same period last year.

      [1] This announcement contains translations of certain RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations of RMB into U.S. dollars are made at a rate of RMB7.2672 to US$1.00, the noon buying rate in New York City for cable transfers payable in RMB, as certified for customs purposes by the Federal Reserve Bank of New York on June 28, 2024.

      [2] Non-GAAP net loss and non-GAAP basic and diluted loss per share for Class A and Class B ordinary shares are defined as their most directly comparable GAAP measures excluding the impact of share-based compensation expenses.

      [3] Adjusted EBITDA is defined as net income/(loss) plus interest expenses, net, income tax expenses, depreciation and amortization, share-based compensation expenses and other adjustments. Other adjustments include foreign exchange loss, net, other income, net, gain on disposal of equity method investment, gain on disposal of subsidiaries, change in fair value of derivative liability, changes in fair value of short-term investments and gain on disposal of long-lived equipment.

      Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical, commented, "In the past few years, Concord Medical has been actively building a solid foundation for its business development, as well as looking to the future by profoundly enhancing its expertise in oncology care and strengthening the competitiveness of its international diagnosis and treatment services. Concurrently, Concord Medical has been continually exploring the untapped potential of its network business, striving for growth and expansion.

      We are delighted to announce that, Guangzhou Concord Cancer Center ("Guangzhou Hospital"), a PRC subsidiary of our Company offering comprehensive cancer care services, has obtained the large medical equipment procurement license for its proton equipment, as announced by the National Health Commission of the PRC on September 14, 2024. Proton therapy services stand as a pivotal segment within Concord Medical's hospital business, anticipated to deliver a significant boost to our revenue base upon its successful implementation. This endeavor will concurrently elevate Guangzhou Hospital's profile and reputation. Looking ahead, we maintain a positive outlook on the growth potential of this sector, expecting continued development and expansion through 2025 and beyond."

      2024 First Half Financial Results

      Net Revenues

      Hospital Business

      Net revenues from the hospital business were RMB137.8 million (US$19.0 million) in the first half of 2024, representing a 13.2% decrease from net revenues of RMB158.7 million in the first half of 2023, mainly because (1) we downsized certain of our hospital business with lower profit margin, and (2) as we concentrated the resources in preparing our proton therapy business, the revenue from the medical institutions fluctuated in the short term.

      Network Business

      Net revenues from the network business were RMB81.0 million (US$11.1 million), representing a 35.6% decrease from net revenues of RMB125.8 million in the first half of 2023, mainly because of the decreased demand for medical equipment, software and the relevant management and technical support services by our customers in current economic environment.

      Cost of Revenues

      Hospital Business

      Cost of revenues of the hospital business in the first half of 2024 was RMB174.0 million (US$23.9 million), representing a 14.9% decrease from cost of revenues of RMB204.4 million in the first half of 2023, mainly because of (1) our overall efforts to improve operation efficiency and reduce costs, especially for staff costs, and (2) the decrease of consumables and maintenance cost, lease cost and staff cost along with the fluctuation in hospital business.

      Network Business

      Cost of revenues of the network business was RMB86.4 million (US$11.9 million), representing a 26.4% decrease from RMB117.5 million in the first half of 2023, generally in line with the decrease in the business scale and revenue generated from sales and installation of medical equipment and software, management and technical support services.

      Gross Loss and Gross Loss Margin

      Hospital Business

      Gross loss from the hospital business was RMB36.2 million (US$4.9 million) in the first half of 2024, compared to RMB45.7 million in the same period last year. The gross loss margin of the hospital business for the first half of 2024 was 26.3%, compared to the gross loss margin of 28.8% for the same period last year. The improvement in gross loss margin of the hospital business was primarily because of our overall efforts to improve operation efficiency and reduce costs.

      Network Business

      Gross loss from the network business was RMB5.4 million (US$0.8 million), compared to the gross profit of RMB8.3 million in the first half of 2023. The gross loss margin of the network business for the first half of 2024 was 6.7%, relatively stable compared to the gross profit margin of 6.6% for the same period last year.

      Operating Expenses

      Selling expenses were RMB25.0 million (US$3.4 million) in the first half of 2024, compared to RMB26.4 million in the first half of 2023. Selling expenses as a percentage of net revenues was 11.4% in the first half of 2024, compared to 9.3% in the first half of 2023.

      General and administrative expenses were RMB131.2 million (US$18.1 million) in the first half of 2024, of which employee benefit expenses were RMB62.4 million (US$8.6 million). In the same period of last year, general and administrative expenses were RMB150.2 million. The decrease was mainly attributable to the decrease in staff cost and our overall efforts to improve operation efficiency. General and administrative expenses as a percentage of net revenues was 59.9% in the first half of 2024, compared to 52.8% in the first half of 2023.

      Capital Expenditures

      Comparing to RMB46.5 million in the first half of 2023, capital expenditures were RMB168.4 million (US$23.2 million) in the first half of 2024, mainly due to the increase in deposit for non-current assets and construction fees for our hospital business.

      Accounts Receivable

      As of June 30, 2024, accounts receivable were RMB78.2 million (US$10.8 million), representing a 6.4% increase from accounts receivable of RMB73.5 million as of December 31, 2023. The average period of sales outstanding for accounts receivable (also known as days sales outstanding) was 171 days in the first half of 2024.

      Bank Loans and Other Borrowings

      As of June 30, 2024, the Company had bank loans and other borrowings totaling RMB3.4 billion (US$463.6 million).

      About Non-GAAP Financial Measures

      To supplement the consolidated financial statements presented in accordance with United States Generally Accepted Accounting Principles ("GAAP"), Concord Medical uses certain non-GAAP measures. The Company presents certain of its financial information that is adjusted from results based on GAAP to exclude the impact of share-based compensation expenses, such as non-GAAP net loss and non-GAAP basic and diluted loss per share for Class A and Class B ordinary shares. The Company believes excluding share-based compensation expenses from its GAAP financial measures is useful for its management and investors to assess and analyze the Company's core operating results, as such expense is not directly attributable to the underlying performance of the Company's business operations and do not impact its current cash earnings. Concord Medical also believes these non-GAAP measures excluding share-based compensation expenses are important in helping investors to understand the Company's current financial performance and future prospects and to compare business trends among different reporting periods on a consistent basis. In addition, Concord Medical also presents the non-GAAP measure of adjusted EBITDA, which is defined in this announcement as net loss plus interest expenses, net, income tax expenses, depreciation and amortization, share-based compensation expenses and other adjustments. Other adjustments include foreign exchange loss, net, other income, net, gain on disposal of equity method investment, gain on disposal of subsidiaries, change in fair value of derivative liability, changes in fair value of short-term investments and gain on disposal of long-lived equipment. Furthermore, adjusted EBITDA eliminates the impact of items that the Company does not consider to be indicative of the performance of the network business and hospital business. The Company believes investors will similarly use adjusted EBITDA as one of the key metrics to evaluate its financial performance and to compare its current operating results with corresponding historical periods and with other companies in the healthcare services industry. The presentation of these additional measures should not be considered a substitute for or superior to GAAP results or as being comparable to results reported or forecasted by other companies. The non-GAAP measures have been reconciled to GAAP measures in the attached financial information.

      About Concord Medical

      Concord Medical Services Holdings Limited is a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across China. For more information, please see http://ir.ccm.cn.

      Safe Harbor Statement

      This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company's control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

      Concord Medical Services Holdings Co., Ltd.


      Consolidated Balance Sheets
      (in thousands)





      December 31,





      2023


      June 30, 2024



      RMB


      RMB


      US$



      (Audited)


      (Unaudited)


      (Unaudited)


      ASSETS







      Current assets







      Cash and cash equivalents

      58,139


      115,667


      15,916


      Short-term investment

      -


      211,238


      29,067


      Restricted cash, current portion

      32,280


      10,116


      1,392


      Accounts receivable, net

      73,496


      78,222


      10,764


      Prepayments and other current assets, net

      412,946


      574,330


      79,030


      Inventories

      40,347


      39,832


      5,481


      Total current assets

      617,208


      1,029,405


      141,650


       

      Non-current assets







      Property, plant and equipment, net

      3,546,873


      3,555,860


      489,303


      Right-of-use assets, net

      580,365


      538,514


      74,102


      Goodwill

      575,427


      572,216


      78,740


      Intangible assets, net

      323,287


      300,569


      41,360


      Deposits for non-current assets

      4,646


      139,085


      19,139


      Long-term investments

      394,711


      480,873


      66,170


      Other non-current assets

      11,426


      6,171


      849


      Total non-current assets

      5,436,735


      5,593,288


      769,663









      Total assets

      6,053,943


      6,622,693


      911,313


       

      LIABILITIES AND EQUITY







      Current liabilities







      Accounts payable

      129,236


      127,334


      17,522


      Accrued expenses and other liabilities

      731,793


      740,827


      101,940


      Income tax payable

      1,522


      1,581


      218


      Operating lease liabilities, current

      46,492


      35,700


      4,912


      Short-term bank and other borrowings

      319,625


      363,446


      50,012


      Long-term bank and other borrowings, current portion

      722,563


      793,760


      109,225


      Derivative liability

      163


      109,632


      15,086


      Total current liabilities

      1,951,394


      2,172,280


      298,915


       

      Non-current liabilities







      Long-term bank and other borrowings, non-current portion

      1,994,014


      2,211,862


      304,362


      Deferred tax liabilities

      99,538


      92,807


      12,771


      Operating lease liabilities, non-current

      193,007


      159,461


      21,943


      Other long-term liabilities

      69,003


      65,397


      9,000


      Total non-current liabilities

      2,355,562


      2,529,527


      348,076


       

      Total liabilities

      4,306,956


      4,701,807


      646,991


      EQUITY







      Class A ordinary shares

      68


      68


      9


      Class B ordinary shares

      37


      37


      5


      Treasury stock

      (7)


      (7)


      (1)


      Additional paid-in capital

      2,007,965


      2,169,695


      298,560


      Accumulated other comprehensive loss

      (65,419)


      (71,694)


      (9,865)


      Accumulated deficit

      (4,064,589)


      (4,236,847)


      (583,010)


      Total Concord Medical Services Holdings Limited shareholders' deficit

      (2,121,945)


      (2,138,748)


      (294,302)


      Noncontrolling interests

      3,868,932


      4,059,634


      558,624









      Total equity

      1,746,987


      1,920,886


      264,322









      Total liabilities and equity

      6,053,943


      6,622,693


      911,313


      Concord Medical Services Holdings Co., Ltd.

      Consolidated Profit & Loss

      (in thousands, except for number of shares and per share data)



      June 30,
      202
      3


      June 30, 2024


      RMB


      RMB


      US$


      (Unaudited)


      (Unaudited)


      (Unaudited)

      Revenues, net of business tax, value-added tax and related
      surcharges






      Hospital

      158,707


      137,772


      18,958

      Network

      125,806


      81,038


      11,151

      Total net revenues

      284,513


      218,810


      30,109

      Cost of revenues:






      Hospital

      (204,433)


      (173,963)


      (23,938)

      Network

      (117,503)


      (86,443)


      (11,895)

      Total cost of revenues

      (321,936)


      (260,406)


      (35,833)







      Gross loss

      (37,423)


      (41,596)


      (5,724)







      Operating expenses:






      Selling expenses

      (26,362)


      (24,975)


      (3,437)

      General and administrative expenses

      (150,240)


      (131,173)


      (18,050)







      Operating loss

      (214,025)


      (197,744)


      (27,211)

      Interest expense

      (84,374)


      (68,668)


      (9,449)

      Foreign exchange loss, net

      (2,444)


      (30,269)


      (4,165)

      Gain on disposal of long-lived equipment

      62


      -


      -

      Interest income

      5,800


      5,990


      824

      Change in fair value of derivative liability

      -


      (108,777)


      (14,968)

      Income from equity method investments

      10,099


      6,070


      835

      Gain on disposal of subsidiaries

      -


      47,997


      6,605

      Other income, net

      13,623


      1,388


      191

      Gain on disposal of equity method investment

      37,498


      -


      -

      Changes in fair value of short-term investments

      -


      6,631


      912







      Loss before income tax

      (233,761)


      (337,382)


      (46,426)

      Income tax expenses

      23,417


      8,674


      1,194

      Net loss

      (210,344)


      (328,708)


      (45,232)







      Net loss attributable to noncontrolling interests

      (119,359)


      (156,450)


      (21,528)

      Net loss attributable to Concord Medical Services Holdings
      Limited

      (90,985)


      (172,258)


      (23,704)







      Loss per share for Class A and Class B ordinary shares






      Basic

      (0.69)


      (1.31)


      (0.18)

      Diluted

      (0.69)


      (1.31)


      (0.18)







      Weighted average number of class A and class B ordinary shares
      outstanding:






      Basic

      131,053,858


      131,053,858


      131,053,858

      Diluted

      131,053,858


      131,053,858


      131,053,858

      Other comprehensive loss, net of tax of nil






      Foreign currency translation, net of tax of nil

      (17,371)


      (6,273)


      (863)

      Total other comprehensive loss, net of tax

      (17,371)


      (6,273)


      (863)

      Comprehensive loss

      (227,715)


      (334,981)


      (46,095)

      Comprehensive loss attributable to noncontrolling interests

      (119,359)


      (156,450)


      (21,528)

      Comprehensive loss attributable to Concord Medical Services
      Holdings Limited's shareholders

      (108,356)


      (178,531)


      (24,567)

      Reconciliations of non-GAAP results of operations measures to the
      nearest comparable GAAP measures

      (in RMB thousands, except per share data unaudited)




      For the six months ended


      For the six months ended



      June 30, 2023


      June 30, 2024







      Non-






      Non-



      GAAP




      GAAP


      GAAP




      GAAP



      Measure


      Adjustment


      Measure


      Measure


      Adjustment


      Measure

      Operating loss


      (214,025)


      -


      (214,025)


      (197,744)


      -


      (197,744)

      Net loss


      (210,344)


      -


      (210,344)


      (328,708)


      -


      (328,708)

      Basic loss per share for
        Class A and

      Class B ordinary
        shares


      (0.69)


      -


      (0.69)


      (1.31)


      -


      (1.31)

      Diluted loss per share
        for Class A and

      Class B ordinary
        shares


      (0.69)


      -


      (0.69)


      (1.31)


      -


      (1.31)














      Reconciliation from net income to adjusted EBITDA(*) (in RMB 
      thousands, unaudited)



      For the six months ended


      For the six months ended


      June 30, 2023


      June 30, 2024

      Net loss

      (210,344)


      (328,708)

      Interest expenses, net

      78,574


      62,678

      Income tax expenses

      (23,417)


      (8,674)

      Depreciation and amortization

      55,537


      43,654

      Share-based compensation

      -


      -

      Other adjustments

      (48,739)


      83,030

      Adjusted EBITDA

      (148,389)


      (148,020)

      EBITDA margin

      -52 %


      -68 %


      (*) Definition of adjusted EBITDA: Adjusted EBITDA is defined as net loss plus interest expenses, net, income tax expenses,
      depreciation and amortization, share-based compensation expenses and other adjustments. Other adjustments include foreign
      exchange loss, net, other income, net, gain on disposal of equity method investment, gain on disposal of subsidiaries, change in fair
      value of derivative liability, changes in fair value of short-term investments and gain on disposal of long-lived equipment. 

      SOURCE Concord Medical Services Holdings Limited

      Modal title

      Also from this source

      Concord Medical Files Annual Report on Form 20-F for the Fiscal Year 2025

      Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment,...

      Concord Medical Schedules 2025 Annual Meeting of Shareholders

      Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment,...

      More Releases From This Source

      Explore

      Medical Equipment

      Medical Equipment

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Banking & Financial Services

      Banking & Financial Services

      Health Care & Hospitals

      Health Care & Hospitals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.